Education
About Us
Working with TipRanks
Follow Us
NeueHealth Inc (NEUE)
NYSE:NEUE
Top Page
NeueHealth Inc
(NYSE:NEUE)
Select Model
Select Model
Rating:51Neutral
Price Target:
$7.00
▲(4.17% Upside)
The overall stock score of 51 reflects significant financial challenges, including negative profitability and cash flow issues, which are partially offset by positive earnings call sentiment and mild bullish technical indicators. The negative P/E ratio and lack of dividend yield further weigh on the score.
NeueHealth Inc (NEUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$60.64M
Dividend YieldN/A
Average Volume (3M)7.04K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth-13.83%
EPS Growth87.09%
CountryUS
Employees986
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-1.68
Shares Outstanding9,024,240
10 Day Avg. Volume5,611
30 Day Avg. Volume7,038
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap20.64
Enterprise Value/Revenue1.41
Enterprise Value/Gross Profit5.81
Enterprise Value/Ebitda-58.26
Forecast
1Y Price Target
$7.00Price Target Upside4.17% Upside
Rating ConsensusHold
Number of Analyst Covering0
NeueHealth Inc Business Overview & Revenue Model
Company DescriptionNeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.
How the Company Makes MoneyNeueHealth generates revenue through multiple streams, including subscription fees from healthcare providers for access to its digital health platform, transaction fees from telehealth consultations, and licensing fees for its data analytics tools. Additionally, the company may engage in strategic partnerships with healthcare organizations, insurance companies, and technology firms to expand its service offerings and reach. These collaborations can lead to revenue-sharing agreements, further enhancing its income potential. The increasing demand for telehealth services and digital health solutions, accelerated by the COVID-19 pandemic, has significantly contributed to NeueHealth's growth and revenue generation.
NeueHealth Inc Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment, highlighted by significant growth in consumer numbers, adjusted EBITDA profitability, and strategic expansions and collaborations. Despite a slight decrease in revenue, the company's advancements in their care model and data analytics platform indicate a positive trajectory.Q2-2025 Updates
Positive Updates
Adjusted EBITDA Profitability
NeueHealth achieved adjusted EBITDA profitability of $19 million in the second quarter, contributing to a total of $32.5 million for the first half of the year.
Consumer Growth
The company served 694,000 consumers in the second quarter, marking a 45% increase compared to the same period last year.
ACA Marketplace Performance
Served 485,000 ACA Marketplace consumers with differentiated results and improved medical loss ratio performance.
Collaborations and Expansions
NeueHealth began operating clinics inside Walgreens locations in Florida, expanding access to care with services including primary care and dermatology.
Medicaid and Provider Enablement
Served 144,000 Medicaid consumers with a strong focus on performance-based arrangements and partnerships with provider groups.
NeuePulse Platform Development
Advancement of NeuePulse platform integrating population health tools and care delivery solutions, aiming to align financing and care delivery.
Negative Updates
Revenue Decrease
Consolidated revenue for the second quarter was $209.1 million, slightly lower than the prior year due to a shift in membership mix.
Company Guidance
During the Second Quarter 2025 Earnings Call, NeueHealth reported a robust performance with significant metrics highlighting their success. The company achieved an adjusted EBITDA of $19 million for the quarter, contributing to a total of $32.5 million for the first half of the year. Revenue for the quarter stood at $209.1 million, driven by serving 694,000 consumers—a remarkable 45% increase compared to the previous year. The ACA Marketplace saw 485,000 consumers, while the senior care business served 65,000 consumers across Medicare Advantage, ACO REACH, and MSSP. Medicaid consumer numbers reached 144,000, with a focus on provider enablement. NeueHealth's innovative NeuePulse platform is expected to streamline care delivery further. The company ended the quarter with $234.4 million in total cash and investments, with $145.5 million in nonregulated cash and short-term investments. Overall, the call underscored NeueHealth's strategic growth and commitment to value-based, consumer-centric care.NeueHealth Inc Financial Statement Overview
Summary
NeueHealth Inc is facing significant financial challenges, with declining revenues, negative profitability margins, and a weak balance sheet characterized by negative equity. Cash flow issues further exacerbate the situation, with negative growth and operational inefficiencies.Income Statement
NeueHealth Inc has experienced declining revenue growth, with a negative growth rate of -1.86% in the TTM period. The company also shows negative profitability margins, including a net profit margin of -10.71% and an EBIT margin of -5.55%, indicating ongoing operational challenges. Despite a slight improvement in gross profit margin to 24.21% in the TTM, the overall financial health remains weak.30
Negative
Balance Sheet
The balance sheet reflects significant financial instability, with negative stockholders' equity and a concerning return on equity of 14.26% in the TTM, driven by negative net income. The debt-to-equity ratio is negative due to negative equity, indicating potential solvency issues. The equity ratio is also negative, highlighting a precarious financial position.20
Very Negative
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, with a free cash flow growth rate of -25.08% in the TTM. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income to cash. However, the free cash flow to net income ratio of 1.06 indicates some ability to cover net losses with free cash flow.25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 890.44M | 936.66M | 1.16B | 751.16M | 1.51B | 514.89M |
| Gross Profit | 215.55M | 194.52M | 164.22M | 88.19M | 218.88M | 62.97M |
| EBITDA | -21.48M | -65.11M | -566.80M | -318.18M | -308.58M | -257.60M |
| Net Income | -95.38M | -134.68M | -1.15B | -1.46B | -1.18B | -248.44M |
Balance Sheet | ||||||
| Total Assets | 743.69M | 544.38M | 1.23B | 4.67B | 3.60B | 1.81B |
| Cash, Cash Equivalents and Short-Term Investments | 145.56M | 93.17M | 93.56M | 217.88M | 289.28M | 988.30M |
| Total Debt | 1.00M | 204.61M | 370.35M | 350.06M | 155.00M | 28.42M |
| Total Liabilities | 1.14B | 930.49M | 1.48B | 3.73B | 2.32B | 2.27B |
| Stockholders Equity | -448.78M | -434.69M | -343.53M | 719.93M | 1.15B | 1.18B |
Cash Flow | ||||||
| Free Cash Flow | -74.05M | -125.55M | -2.73B | 207.02M | 51.65M | -63.71M |
| Operating Cash Flow | -69.94M | -123.22M | -2.73B | 234.47M | 82.06M | -57.24M |
| Investing Cash Flow | 56.99M | 186.89M | 1.12B | -429.72M | -552.89M | -689.74M |
| Financing Cash Flow | -35.58M | -253.55M | 49.91M | 1.07B | 1.04B | 712.44M |
NeueHealth Inc Technical Analysis
Positive
6.72
Price Trends
6.72
Positive
6.77
Negative
6.69
Positive
Market Momentum
<0.01
Negative
51.88
Neutral
31.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUE, the sentiment is Positive. The current price of 6.72 is above the 20-day moving average (MA) of 6.68, below the 50-day MA of 6.72, and above the 200-day MA of 6.69, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 31.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEUE.
NeueHealth Inc Risk Analysis
NeueHealth Inc disclosed 59 risk factors in its most recent earnings report. NeueHealth Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeueHealth Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | 148.13M | -86.42 | 20.09% | ― | 0.04% | 98.87% | |
62 Neutral | 2.65B | 17.71 | 60.41% | 1.21% | 0.00% | 0.00% | |
57 Neutral | 113.94M | -2.75 | -83.03% | ― | -9.59% | 8.78% | |
52 Neutral | 155.59M | -1.26 | -26.41% | ― | -45.35% | 96.80% | |
51 Neutral | $60.64M | ― | 84.03% | ― | -13.83% | 87.09% | |
42 Neutral | 77.04M | -0.14 | -381.75% | ― | 63.66% | 36.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NEUE
NeueHealth Inc
6.72
1.53
29.48%
CCLD
CareCloud
3.61
1.04
40.47%
AVTX
Avalo Therapeutics
11.70
2.03
20.99%
CBUS
Cibus
1.36
-2.20
-61.80%
HYPR
Hyperfine
1.45
0.40
38.10%
CON
Concentra Group Holdings Parent, Inc.
20.87
-2.10
-9.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.